Clinical TrialsSearch results
Number of results: 481
Other
- Phase II study of cisplatin, docetaxel, and irinotecan, followed by gefitinib, gemcitabine and vinorelbine for patients with non-small-cell lung cancer harboring active EGFR gene mutations (OLCSG0704)
- non-small-cell lung cancer
- Okayama Lung Cancer Study Group
- 2009-08-01
Other
- Phase II study of erlotinib monotherapy for relapsed patients with non-small-cell lung cancer who do not possess any active EGFR gene mutations
- relapsed non-small-cell lung cancer
- Okayama Lung Cancer Study Group
- 2008-11-16
Other
- Phase II study of irinotecan and amrubicin for relapsed non-small-cell lung cancer
- Relapsed non-small-cell lung cancer
- Okayama Lung Cancer Study Group
- 2005-09-12
Other
- Phase II study of topotecan and amrubicin for metastatic or relapsed small-cell lung cancer
- Metastatic or relapsed small-cell lung cancer
- Okayama Lung Cancer Study Group
- 2005-09-12
Other
- Phase II study of topotecan and cisplatin for elderly small-cell lung cancer
- Elderly small-cell lung cancer
- Okayama Lung Cancer Study Group
- 2005-09-12
Other
- Randomized phase II trial of S-1 plus docetaxel combination versus single-agent docetaxel in platinum-pretreated patients with non-small-cell lung cancer
- platinum-pretreated patients with non-small-cell lung cancer
- Okayama Lung Cancer Study Group
- 2005-09-12
Recruiting
- An Investigator-initiated Clinical Trial, First in Human study, with a natural-type micro RNA MIRX002, for patients with malignant pleural mesothelioma
- Malignant pleural mesothelioma
- Okada Morihito
- 2021-12-09
Recruiting
- Nintedanib for IPF patients with resected NSCLC in JAPAN Phase 2 study
- Idiopathic pulmonary fibrosis, Non-Small Cell Lung Cancer
- Okada Morihito
- 2022-10-20
Other
- An observational study in patients who received nivolumab preoperatively for stage 1 non-small cell lung cancer considered as high-risk of relapse
- non small cell lung cancer
- Okada Morihito
- 2019-06-18
Other
- Preoperative Nivolumab (Opdivo) to evaluate pathologic response in patients with stage I non-small cell lung cancer: a phase 2 trial
- non small cell lung cancer
- Okada Morihito
- 2019-01-29